Trial Profile
Phase II Randomized, Sequential Group, Evaluation of Ascending Reversal Doses of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban Following PER977 Reversal
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ciraparantag (Primary) ; Edoxaban
- Indications Haemorrhage
- Focus Adverse reactions; Therapeutic Use
- Sponsors Perosphere
- 26 Sep 2016 Status changed from recruiting to completed.
- 02 Sep 2015 Results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
- 20 May 2015 Treatment arms changed from 4 to 5 as reported by ClinicalTrials.gov record.